Refractory Anaplastic Astrocytoma
Conditions
Interventions
control group:TMZ standard treatment
Sponsors
ShangHai Gamma Knife Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) postoperative histopathology and molecular confirmed MGMT promoter unmethylation in newly diagnosed anaplastic astrocytoma patients; (2) Aged 18-65 years old; (3) Karnofsky Performance Status (KPS) =60; (4) the expected survival time =6 months; (5) patients were without major organ dysfunction. Specific test index: White blood cells > 4.0×10^9/L; Platelet> 100×10^9/L; Hemoglobin > 10 g/dl; Serum bilirubin was lower than 1.5 times of the maximum normal value; ALT and AST was lower than 2 times of the maximum normal value; Serum creatinine = 1.5 mg/dl; (6) Patients fully understand clinical research protocol and signed the informed consent.
Exclusion criteria
Exclusion criteria: (1) Patients had undergone chemotherapy with TMZ before adjuvant radiotherapy; (2) Patients during pregnancy or lactation; (3) Patients with suppurative and chronic infectious wounds delayed healing; (4) Patients with liver, kidney and heart dysfunction; (5) Patients suffering from a history of mental illness and uneasily controlled epilepsy; (6) Patients was considered not suitable by researchers in this trial; (7) Patients with contraindications to use DDP(such as allergy to Platinum-based drugs); (8) Patients participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival(PFS);Overall Survival(OS);RANO standard;Quality of Life; | — |
Countries
China
Contacts
Public ContactYang Wang
ShangHai Gamma Knife Hospital
Outcome results
None listed